Adenovirus vectors activate Vδ2+ γδT cells in a type I interferon-, TNF-, and IL-18-dependent manner

Nicholas M. Provine*, Ali Amini, Lucy C. Garner, Michael E.B. FitzPatrick, Christina Dold, Laura Silva Reyes, Senthil Chinnakannan, Blanche Oguti, Meriel Raymond, Fulvia Troise, Stefania Capone, Antonella Folgori, Eleanor Barnes, Christine S. Rollier, Andrew J. Pollard, Paul Klenerman

*Corresponding author for this work

Research output: Contribution to journalComment/debate

Original languageEnglish
JournalEuropean Journal of Immunology
DOIs
Publication statusAccepted/In press - 2022
Externally publishedYes

Bibliographical note

Funding Information:
We thank Hussein Al‐Mossawi and ImCheck Therapeutics for reagents and the trial volunteers. The authors received funding from the following organizations: N.M.P. (Oxford‐UCB Postdoctoral Fellowship); A.A. (Wellcome [216417/Z/19/Z]); L.C.G. (Wellcome [109028/Z/15/Z]); M.E.B.F. (Oxford‐Celgene Doctoral Fellowship). E.B. [MRC (STOP‐HCV and MR/R014485/1), NIHR Senior Investigator, NIHR BRC]; C.S.R. (NIHR BRC); A.J.P. (NIHR Senior Investigator); P.K. (Wellcome [WT109965MA], NIHR Senior Investigator). The ChAdOx1 MenB.1 trial is funded by the MRC DPFS (MRM0076931). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health.

Cite this